Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic Study of Methylphenidate in ADHD
NCT00483106Phase 4Completed
- Sponsor
- McGill University
- Start
- Nov 1999
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by McGill University. Primary endpoints: Conners' Global Index - Parent Version at 2 weeks and Conners' Global Index - Teacher Version at 2 weeks. Started Nov 1999; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00483106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483106.